StreetInsider.com News Articles

Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report

Wed, 21 Oct 2026 10:43:00 -0400

NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended September 30, 2026, after the close of the market on Wednesday, November 4, 2026.

The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.

Interested participants in the United States may access the conference call by dialing

Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report

Wed, 21 Oct 2026 10:43:00 -0400

The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.

Interested participants in the United States may access the conference call by dialing

Form 4 Progyny, Inc. For: Oct 14 Filed by: Cummings Melissa B

Fri, 16 Oct 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20261016/27198508.html

Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting

Thu, 15 Oct 2026 09:34:00 -0400

NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, announced today that it will present new research evaluating real-world outcomes from its Menopause and Midlife program and exhibit at The Menopause Society 2026 Annual Meeting in San Diego, October 20 – 24, 2026.

As a leading provider of employer-sponsored menopause care around the globe, Progyny is committed to expanding access to high quality, evidence-based care and demonstrating its impact on women's health outcomes. The

Progyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting

Thu, 15 Oct 2026 09:34:00 -0400

Form 144 Progyny, Inc. Filed by: Cummings Melissa B

Wed, 14 Oct 2026 13:51:00 -0400

si-local-file:///var/storage/secattach/20261014/27186495.html

Progyny expects 1.2 million new covered lives in 2027 selling season

Wed, 07 Oct 2026 08:29:33 -0400

Progyny, Inc. (Nasdaq: PGNY) said its current annual selling season is on pace to reach a record level for new covered lives added to its managed fertility solution, based on commitments received and anticipated remaining decisions.

The New York-based company expects approximately 1.2 million new covered lives from client launches planned throughout the first half of 2027, according to a statement released Oct. 7, 2026.

Chief Executive Officer Pete Anevski attributed the selling season results in part to rising overall medical plan costs projected for 2027. "We believe it isn't coincidental that we're seeing these strong results given the expected record increases

Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics

Wed, 07 Oct 2026 08:28:58 -0400

Expecting 1.2 Million New Covered Lives from Commitments to Date and Anticipated Remaining Decisions

Reflects How Employers are Increasingly Turning to Solutions with a Proven Track Record of Delivering Savings, Total Cost Management and ROI

Progyny’s Solutions Creating Compelling Opportunities for Employers to Stem Impacts from Broader Medical Cost Inflation Trend While Maintaining or Expanding Coverage of Services Impactful to their Workforce

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today revealed

Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics

Wed, 07 Oct 2026 08:28:58 -0400

Expecting 1.2 Million New Covered Lives from Commitments to Date and Anticipated Remaining Decisions

Reflects How Employers are Increasingly Turning to Solutions with a Proven Track Record of Delivering Savings, Total Cost Management and ROI

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today revealed

Form 4 Progyny, Inc. For: Sep 23 Filed by: Swartz Allison

Mon, 28 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260928/27114964.html

Form 144 Progyny, Inc. Filed by: Swartz Allison

Wed, 23 Sep 2026 11:37:00 -0400

si-local-file:///var/storage/secattach/20260923/27095141.html

Form 4 Progyny, Inc. For: Sep 17 Filed by: Clapp Geoffrey

Mon, 21 Sep 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260921/27086086.html

Form 4/A Progyny, Inc. For: Sep 10 Filed by: GORDON KEVIN K

Fri, 18 Sep 2026 18:47:00 -0400

si-local-file:///var/storage/secattach/20260918/27081484.html

Form 4 Progyny, Inc. For: Sep 10 Filed by: GORDON KEVIN K

Mon, 14 Sep 2026 17:54:00 -0400

si-local-file:///var/storage/secattach/20260914/27059550.html

Form 144 Progyny, Inc. Filed by: GORDON KEVIN K

Thu, 10 Sep 2026 13:58:00 -0400

si-local-file:///var/storage/secattach/20260910/27047724.html

Progyny (PGNY) PT Raised to $33 at Citizens on CalPERS Selection as Fertility Benefits Partner

Tue, 08 Sep 2026 04:27:56 -0400

Citizens analyst Constantine Davides raised the price target on Progyny (NASDAQ: PGNY) to $33.00 (from $31.00) while maintaining a Market Outperform rating.

The analyst commented, "We understand that CalPERS (the California Public Employees' Retirement System) has selected Progyny (PGNY) as its fertility benefits partner, effective July 1, 2027. CalPERS is the second-largest public purchaser of health benefits in the nation behind only the federal government, securing health benefits for all California state employees, as well as for the employees of ~1.3K public school districts and ~1.5K local agencies. The organization has ~1.5M covered lives enrolled in its health plans; 888K (~60%)

Progyny (PGNY) PT Raised to $33 at Citizens on CalPERS Selection as Fertility Benefits Partner

Tue, 08 Sep 2026 04:27:56 -0400

Citizens analyst Constantine Davides raised the price target on Progyny (NASDAQ: PGNY) to $33.00 (from $31.00) while maintaining a Market Outperform rating.

Progyny (PGNY) Reiterated at Market Outperform by Citizens as Addressable Market Grows

Wed, 02 Sep 2026 04:19:23 -0400

Citizens analyst Constantine Davides reiterated a Market Outperform rating and $31.00 price target on Progyny (NASDAQ: PGNY).

The analyst commented, "The pooled risk, fixed premium offering is expected to expand PGNY's addressable market by 50M lives. While we do not foresee a material contribution from Select in its first year (2027), the company's historical success at scaling its other solutions gives us conviction in the potential for Select to meaningfully ramp over the next several years. We believe Select could generate $130M+ of margin-accretive revenue by 2030, assuming 1% penetration into its addressable market. We have not yet factored a contribution

Progyny (PGNY) PT Raised to $30 at JPMorgan

Fri, 21 Aug 2026 09:31:58 -0400

JPMorgan analyst Lisa Gill raised the price target on Progyny (NASDAQ: PGNY) to $30.00 (from $27.00) while maintaining a Neutral rating.

Wells Fargo Starts Progyny (PGNY) at Overweight

Thu, 20 Aug 2026 04:55:58 -0400

Wells Fargo initiates coverage on Progyny (NASDAQ: PGNY) with a Overweight rating and a price target of $37.00.

For an analyst ratings summary and ratings history on Progyny click here. For more ratings news on Progyny click here.

Shares of Progyny closed at $25.53 yesterday.

Progyny (PGNY) PT Raised to $36 at Truist Securities

Thu, 13 Aug 2026 07:10:44 -0400

Truist Securities analyst Jailendra Singh raised the price target on Progyny (NASDAQ: PGNY) to $36.00 (from $33.00) while maintaining a Buy rating.

Progyny (PGNY) PT Lowered to $30 at Barclays

Wed, 12 Aug 2026 05:26:46 -0400

Barclays analyst Peter Warendorf lowered the price target on Progyny (NASDAQ: PGNY) to $30.00 (from $34.00) while maintaining a Equalweight rating.

Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference

Fri, 07 Aug 2026 10:51:00 -0400

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET.

Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny’s investor relations website at http://investors.progyny.com.

About Progyny

Progyny (Nasdaq: PGNY) is a global leader in women's health

Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference

Fri, 07 Aug 2026 10:51:00 -0400

Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny’s investor relations website at http://investors.progyny.com.

About Progyny

Progyny (Nasdaq: PGNY) is a global leader in women's health

Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference

Fri, 07 Aug 2026 10:51:00 -0400

Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny’s investor relations website at http://investors.progyny.com.

About Progyny

Progyny (Nasdaq: PGNY) is a global leader in women's health